Anti-STING Constitutively Active Mutant (R284M)

Stimulator of interferon genes (STING) is a component of the innate immune response that binds to cyclic dinucleotides, which are bacterial second messengers, leading to activation of NF-kappaB and transcription of immunomodulatory genes, including type I interferon (IFN). The R284M mutation in STING is associated with constitutive activation of downstream signaling. It increases the propensity of STING to dimerize and associate with the kinase TBK1 (Cay-22817), enhancing the ability of STING to activate IRF3 (Cay-22811) and NF-kappaB (Cay-10009818) and induce a type I IFN response. However, the R284M mutation occurs outside of the dimerization region between positions 153-177, so rather than a direct effect on dimerization, it is predicted to promote or inhibit binding of a cellular factor that stabilizes or impairs STING dimerization. Cayman's STING M284 variant Polyclonal Antibody preferentially detects overexpressed STING (R284M) versus wild-type STING by Western blot.Synonyms: Endoplasmic Reticulum Interferon Stimulator, ERIS, Mediator of IRF3 Activation, MITA, MPYS, Stimulator of Interferon Genes, TMEM173, Transmembrane Protein 173. Immunogen: Synthetic peptide from the internal region of human STING protein containing the M284 mutation. Formulation: (Request formulation change), 500 µl of peptide affinity-purified polyclonal antibody. Storage Buffer: PBS, pH 7.2, containing 50% glycerol and 0.02% sodium azide. Host: Rabbit. Isotype: IgG. Applications: WB at 1:200. Cross Reactivity: (-) Wild-type STING. UniProt Accession #: Q86WV6.